The GALAXY-1 clinical trial examines patients with advanced lung adenocarcinoma, a type of non-small cell lung cancer (NSCLC), receiving either ganetespib (a new cancer drug) and docetaxel (Taxotere, a chemotherapy drug) or Taxotere alone as second-line treatment. Recent interim results show ganetespib-treated patients surviving 10.4 months on average (vs 8.4 months in the Taxotere-only group) and experiencing a 10% reduction in the risk of death. This is a smaller difference than was seen in preliminary results in September, 2012 and June, 2013 (31% and 18% reduction in risk of death, respectively). It is also unclear whether the effect is indeed caused by ganetespib or due to chance. However, the drug’s makers emphasize that ganetespib may be more effective in certain patient subgroups.